# SOCIUM

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/socium

- Industry: Pharmaceuticals
- Headquarters: Tokyo, Japan
- Website: www.socium.co.jp
- Total disclosed funding: $4.7M
- Latest round: Series B (Dec 26, 2020)
- Investors on record: 1

## About

SOCIUM Inc. is a Tokyo-based pharmaceutical research company focused on drug discovery and analytical services, offering innovative solutions for the biotechnology and pharmaceutical sectors.Founded in 2017, SOCIUM Inc. operates primarily from Tokyo, Japan, specializing in drug discovery. The company has completed three deals, with its most recent funding round being a Series B in July 2021, where it raised JPY 10 million from the National Institute of Advanced Industrial Science and Technology. The firm is currently valued at JPY 1,980.426 million.SOCIUM Inc. specializes in drug discovery and related analytical services, concentrating on innovative solutions for biotechnology and pharmaceutical sectors. Their primary offerings include phosphorylation analysis services that facilitate understanding of molecular mechanisms in drug candidates. They also provide consulting services to help clients navigate drug development complexities. Collaborating with institutions like Nanjing Medical University and Huaxi Hospital of Sichuan University, they enhance research in treating amyotrophic lateral sclerosis (ALS). SOCIUM serves clients across North America, Asia, and Europe, focusing on biotechnology firms, pharmaceutical companies, and academic research institutions.SOCIUM Inc. generates revenue through service contracts and partnerships with both public and private sector organizations. The company operates under a contract research model, where clients hire SOCIUM for specific projects involving detailed studies of drug candidates and their molecular interactions. This model typically involves project-based fees negotiated at the outset, enabling tailored solutions for clients' unique research needs. The firm also engages in collaborations that enhance service offerings and market reach, and may include licensing agreements for proprietary technologies developed through joint research efforts, ensuring financial stability and ongoing innovation in drug discovery.In July 2021, SOCIUM Inc. raised JPY 10 million in Series B funding to accelerate its business expansion and increase its value. The company is focused on developing new products and services while targeting increased market penetration in specific regions. Future plans include expanding into new markets, although specific regions have not been disclosed. The recent funding will support these initiatives to enhance their research capabilities and business operations.

## Funding rounds

- Series B, Dec 26, 2020, $2.4M — University of Tokyo Edge Capital Partners
- Series A, Oct 12, 2018, $2.3M — University of Tokyo Edge Capital Partners

## Investors

- University of Tokyo Edge Capital Partners (https://capitalatlas.ai/funds/university-of-tokyo-edge-capital-partners) — Series A, Series B